INOMAX®(NITRIC OXIDE) FOR INHALATION
An essential therapy with world-class support
The first of our growing list of critical care therapies is INOMAX, an effective intervention for term and near-term infants who suffer from hypoxic respiratory failure (HRF) associated with pulmonary hypertension.1 Since its commercialization in 2000, we believe that approximately 394,000 patients have been treated with INOMAX worldwide.2
Our experience with INOMAX has taught us that supporting the critical care treatment community takes more than an effective therapy. It takes a commitment to meeting the specialized needs of this environment. From flying in necessary equipment to emergency drug delivery and middle-of-the-night technical assistance, we do what it takes to extend the benefits of INOMAX to patients in need.
Wherever and whenever you need us, we're there
“I currently serve as a neonatologist and Chief of Pediatrics at Tripler Army Medical Center. I wanted to drop you a quick note to comment on the excellent support we recently received from Mr. Eddie Costa of Ikaria in helping in arrangements for the transport of a critically ill neonatal patient from Honolulu to Boston. This patient had need for NO (inhaled nitric oxide) on transport and Mr. Costa not only was instrumental in setting up equipment for us for transport, but also insuring that the Medevac team from Aero Medevac in San Diego was properly trained in its use prior to the transport. This was outstanding customer support to us and we greatly appreciated it. Mr. Costa has a long history of providing just such support to us at Tripler and he definitely went the extra mile in his support of our care of this critically ill patient. Please let him know we greatly appreciate his expertise and support.”
Mark W. Thompson
COL MC USA
Chief, Tripler Army Medical Center Dept of Pediatrics
Pediatric Consultant to Surgeon General (General Pediatrics)
Honolulu, HI
For more information on INOMAX, please visit www.INOMAX.com and the therapies section of this website.
Important Safety Information
INOMAX is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
The safety and effectiveness of inhaled nitric oxide have been established in a population receiving other therapies for hypoxic respiratory failure, including vasodilators, intravenous fluids, bicarbonate therapy, and mechanical ventilation.
- INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
- Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration. Caution should be used when administering INOMAX with other drugs that can cause methemoglobinemia regardless of their route of administration
- Nitrogen dioxide (NO2) rapidly forms in gas mixtures containing nitric oxide and oxygen. NO2 formed in this way can cause airway inflammation and damage
- INOMAX must be administered through a system that does not cause excessive generation of NO2 and that monitors for NO, NO2, and FiO2
- Abrupt discontinuation of INOMAX therapy can lead to worsening of PaO2 and increasing pulmonary artery pressure (PAP). Deterioration in oxygenation and elevation in PAP can also occur in children with no apparent response to INOMAX
- In patients with pre-existing left ventricular dysfunction, inhaled nitric oxide may increase pulmonary capillary wedge pressure leading to pulmonary edema
Please see full Prescribing Information.
References
- INOMAX [package insert]. Clinton, NJ: INO Therapeutics LLC; 2011.
- Data on file. Clinton, NJ: Ikaria, Inc; 2009.
INOMAX is a registered trademark of INO Therapeutics LLC.
RSS Feed